EUVIMEDEUVIMED entdecken
Crossref

Diboronate-Modified Hyaluronic Acid for Glucose-Responsive Insulin Delivery

Sijie Xian, Yuanhui Xiang iD, Katarína Mitrová, Jiří Jiráček, Matthew J Webber iD

Biomacromolecules · 14.04.2025 · 26 (4) · 2700-2707

DOI: 10.1021/acs.biomac.5c00144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 27.03.2025. Verfasst von Sijie Xian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana 46556, United States. Hauptthemen laut MEDLINE: Hyaluronic Acid, Insulin, Diabetes Mellitus, Experimental, Boronic Acids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: American Diabetes Association, Leona M. and Harry B. Helmsley Charitable Trust, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes requires precise insulin management to maintain glycemic control and prevent severe complications. Glucose-responsive delivery systems envision an autonomous approach to improve insulin therapy. Here, a glucose-sensitive insulin delivery system comprising hyaluronic acid conjugated with a diboronate glucose binder as a carrier for diol-modified insulin is shown. This approach seeks improved precision in insulin delivery, leveraging bidentate glucose binding to achieve enhanced glucose affinity and specificity. Modification of insulin with a diol motif preserves its native conformation and function. These insulin formulations correct blood glucose in diabetic mice, including glucose-responsive function when subjected to a glucose challenge. However, the absence of secondary interactions, such as electrostatic complexation, ultimately limits the duration of function relative to that of previous platforms. Integrating complementary interactions alongside dynamic-covalent glucose binders therefore enhances the functional duration and therapeutic efficacy in the design of glucose-responsive polymeric carriers, offering design insights into the development of new carriers for glucose-responsive insulin delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronic AcidInsulinDiabetes Mellitus, ExperimentalBoronic AcidsGlucoseDrug Delivery SystemsDrug CarriersHypoglycemic AgentsAnimalsMiceBlood GlucoseMale

Substanzen

Hyaluronic AcidInsulinBlood GlucoseBoronic AcidsGlucoseDrug CarriersHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana 46556, United States.
  • Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry, Prague 16610, Czech Republic.

ORCID-Profile: Yuanhui Xiang, Matthew J Webber

Förderung

  • American Diabetes Association
  • Leona M. and Harry B. Helmsley Charitable Trust
  • National Science Foundation
  • Breakthrough T1D

Zitieren

APA

Xian, S., Xiang, Y., Mitrová, K., Jiráček, J., & Webber, M. J. (2025). Diboronate-Modified Hyaluronic Acid for Glucose-Responsive Insulin Delivery. Biomacromolecules, 26(4), 2700-2707. https://doi.org/10.1021/acs.biomac.5c00144

Vancouver

Xian S, Xiang Y, Mitrová K, Jiráček J, Webber MJ. Diboronate-Modified Hyaluronic Acid for Glucose-Responsive Insulin Delivery. Biomacromolecules. 2025;26(4):2700-2707. doi:10.1021/acs.biomac.5c00144

BibTeX
@article{Xian2025,
  author = {Xian, Sijie and Xiang, Yuanhui and Mitrová, Katarína and Jiráček, Jiří and Webber, Matthew J},
  title = {Diboronate-Modified Hyaluronic Acid for Glucose-Responsive Insulin Delivery},
  journal = {Biomacromolecules},
  year = {2025},
  volume = {26},
  number = {4},
  pages = {2700--2707},
  doi = {10.1021/acs.biomac.5c00144}
}
Kostenlos starten →